pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

4,945 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1830Endpoints1419Fierce Biotech742BioSpace733BioPharma Dive538raps241onclive165fda recalls
therapy area
allOncology12600Rare Disease3288Immunology2965Cardiology2832Hematology2234Pulmonology2204Vaccines
  • J&J to acquire Ollin Biosciences for $2.2 billion to advance bispecific eye drug OLN324 against Roche’s Vabysmo
    Johnson & Johnson announced it will buy Ollin Biosciences for an upfront $2.2 billion, with additional regulatory and commercial milestones that could bring total payments to about $3.3 billion. O…
    Fierce Biotech · 7h agoDealPositive↗ source
  • Helus Pharma's modified psilocybin meets primary and secondary goals in phase 3 depression trial
    Helus Pharma reported that its oral, chemically modified psilocybin candidate, HLP003, was tested in a phase 3 study of 222 patients with major depressive disorder. Participants received a single 1…
    Fierce Biotech · 7h agoPositive readoutPositive↗ source
← prev
page 1 of 198
next →
116
fda medwatch112
globenewswire health73
fda press59
1821
Psychiatry & CNS1225
Ophthalmology1098
Endocrinology & Metabolism794
Pain784
Nephrology767
  • Eli Lilly acquires Calytrix Bio in $1.5 billion deal to add myelofibrosis antibody to its pipeline
    Eli Lilly announced a $1.5 billion acquisition of Massachusetts‑based Calytrix Bio, gaining access to the company’s biparatopic antibody aimed at mutant calreticulin‑driven essential thrombocythemi…
    Fierce Biotech · 7h agoDealPositive↗ source
  • Biogen signs $411 million deal with TrimTech to develop protein degraders for neurodegenerative diseases
    Biogen announced a collaboration with UK‑based TrimTech Therapeutics, valued at up to $411 million in biobucks, to create small‑molecule protein degraders aimed at neurodegenerative disorders. The…
    Fierce Biotech · 7h agoDealPositive↗ source
  • Johnson & Johnson agrees to acquire eye-disease biotech Ollin Biosciences for up to $3.3 billion
    Johnson & Johnson announced Monday that it will purchase Ollin Biosciences, a biotech focused on eye diseases. The transaction is valued at up to $3.3 billion, representing one of the larger recen…
    Endpoints · 2h agoDealPositive↗ source
  • CG Oncology's bladder cancer immunotherapy cuts tumor recurrence risk by 68% in study
    CG Oncology reported that its bladder cancer immunotherapy, cretostimogene, achieved a 68% reduction in tumor recurrence compared with standard care. The treatment uses an engineered common cold v…
    STAT · 3h agoPositive readoutPositive↗ source
  • Eli Lilly to acquire Calytrix Bio for up to $1.5B, targeting rare blood cancers
    Eli Lilly announced it will acquire Calytrix Bio, a Massachusetts biotech, in a deal valued at up to $1.5 billion. Calytrix focuses on precision therapies for myeloproliferative neoplasms, includi…
    BioPharma Dive · 4h agoDealPositive↗ source
  • Flagship Pioneering invests £100 million to launch AI-focused biotech lab in London
    Flagship Pioneering, the life‑science investor behind Moderna, announced the creation of a new laboratory in London. The lab will concentrate on building AI‑native platform companies, using artifi…
    Endpoints · 4h agoDealPositive↗ source
  • Choosing the Right AI Infrastructure Is Key to Accelerating Future Drug Discoveries
    Scientific AI is reshaping drug discovery by allowing developers to predict molecule behavior and design new compounds using models trained on protein structures, genomic data, and experimental res…
    BioPharma Dive · 6h agoNeutral↗ source
  • Clinical AI pilots stall due to organizational environment, not technology
    Clinical teams are increasingly using artificial intelligence to draft regulatory paperwork, assist data review, shape trial design and interpret complex evidence. The technology is proving its val…
    BioPharma Dive · 6h agoNeutral↗ source
  • Seawolf Therapeutics raises $100M and secures up to $1.2B partnership with Sanofi
    Seawolf Therapeutics, a San Diego-based DNA-therapy startup, announced a $100 million financing round as it emerges from stealth. The round was led by Versant Ventures with participation from MPM…
    BioPharma Dive · 6h agoDealPositive↗ source
  • Flagship Pioneering invests £100 million to launch AI-focused biotech incubation lab in London
    Flagship Pioneering announced a £100 million investment to establish its first AI-focused biotech incubation unit outside Cambridge, locating it in London. The new Flagship Origination Lab, U.K.,…
    Fierce Biotech · 10h agoDealPositive↗ source
  • Eli Lilly makes 14th acquisition of 2026, buying a blood-cancer biotech
    Eli Lilly announced it has acquired a blood‑cancer focused biotechnology company, marking its 14th acquisition in 2026. The deal reflects Lilly’s aggressive expansion strategy, funded by strong sa…
    Endpoints · 2h agoDealPositive↗ source
  • CG Oncology's oncolytic therapy shows positive Phase 3 results in non-muscle invasive bladder cancer
    CG Oncology announced that its oncolytic immunotherapy, cretostimogene grenadenorepvec, achieved its primary endpoints in a Phase 3 trial involving patients with non-muscle invasive bladder cancer.…
    Endpoints · 3h agoPositive readoutPositive↗ source
  • Versant and Eli Lilly commit $100 million to launch Seawolf Therapeutics, a non-viral gene-therapy startup
    Versant Ventures, Eli Lilly and other investors announced a $100 million financing round to create Seawolf Therapeutics, a new company focused on non-viral gene delivery. The startup aims to overc…
    STAT · 6h agoDealPositive↗ source
  • AAMC leadership stays vigilant after midterm shift, urges continued congressional support for research
    The Association of American Medical Colleges gathered about 4,100 educators, researchers, clinicians and trainees at its annual meeting in Anaheim, California, a short walk from Disneyland. AAMC C…
    STAT · 7h agoRegulatoryNeutral↗ source
  • Sofinnova Partners raises €725 million for second crossover fund targeting late-stage European biotech firms
    Sofinnova Partners announced the closing of its second crossover fund with €725 million ($815 million) in commitments. The fund is designed to fill the financing gap for late-stage European biopha…
    Endpoints · 9h agoDealPositive↗ source
  • Sofinnova Partners raises €725M crossover fund to back later-stage European biotech firms
    Sofinnova Partners, a leading European life‑science venture firm, announced that it has closed a second crossover fund worth 725 million euros (about $815 million). The new vehicle, called Sofinnov…
    BioPharma Dive · 9h agoDealPositive↗ source
  • Chinese authorities dismiss two researchers after child dies in gene‑editing study
    Chinese authorities have dismissed two researchers involved in a gene‑editing study after a child participant died. State media reported the firings, showing the government's swift response to the…
    Fierce Biotech · 12h agoRegulatoryNegative↗ source
  • Tandem Diabetes Care gets FDA clearance for tubeless insulin delivery system with up to 7-day wear
    Tandem Diabetes Care announced that the FDA has cleared its Tandem Mobi system as a tubeless automated insulin delivery device. The clearance allows the device to be worn for up to seven days witho…
    Fierce Biotech · 14h agoRegulatoryPositive↗ source
  • CDC finds 10% of U.S. adults used GLP-1 drugs in 2025, 20% of them took compounded versions; Russia may seize foreign drug IP
    The Centers for Disease Control and Prevention reported that during July and August 2025 roughly one in ten U.S. adults said they had taken a GLP-1 medication at some point in the prior year. Amon…
    STAT · 2h agoNeutral↗ source
  • Democrats adopt "Medicare for More" as new health-care expansion message
    Democrats in the House have agreed on a new policy slogan, "Medicare for More," signaling a push to broaden health‑care coverage. The phrase is meant to set the agenda apart from the more ambitiou…
    STAT · 3h agoNeutral↗ source
  • San Diego’s Seawolf Therapeutics raises $100M to develop non-viral gene therapies for obesity, muscle loss and osteoporosis
    San Diego‑based Seawolf Therapeutics announced it has closed a $100 million financing round to fund its platform for non‑viral gene therapies. The company says its approach tackles a long‑standing…
    Endpoints · 6h agoDealPositive↗ source
  • New polymer lidding technologies aim to make pharmaceutical blister packs fully recyclable
    Pharmaceutical manufacturers are increasingly prioritizing sustainability in material selection, packaging design and end-of-life handling. The goal is to lower environmental impact while keeping p…
    BioPharma Dive · 6h agoPositive↗ source
  • BeOne Medicines and Hengrui Lead STAT-WireScreen’s China Biotech Powerhouse 25 Ranking
    STAT and risk‑intelligence platform WireScreen have published a new ranking called China’s Biotech Powerhouse 25, which lists the most valuable publicly traded biotech companies in the country. Th…
    STAT · 7h agoNeutral↗ source